KPV: The Alpha-MSH Tripeptide With Two Decades of Preclinical Evidence and an FDA Compounding Vote Nine Days Away

Key takeaways

• KPV (Lys-Pro-Val) is a three-amino-acid C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH), studied for two decades primarily in inflammatory bowel disease, wound healing, and inflammatory skin conditions.
• Its principal mechanism involves intracellular inhibition of NF-κB signalling via the PepT1 di/tripeptide transporter — a route that distinguishes it from most surface-receptor anti-inflammatories.
• The body of evidence is almost entirely preclinical; no large-scale human clinical trials have been completed, a gap the FDA has identified as central to its preliminary position against listing.
• The FDA removed KPV from Category 2 of the 503A Bulk Drug Substances list on 22 April 2026 after nominators withdrew their submissions, placing it in a regulatory grey zone ahead of formal PCAC scrutiny.
• The Pharmacy Compounding Advisory Committee will evaluate KPV on 23 July 2026 at the FDA White Oak Campus, Silver Spring, Maryland.
• FDA staff briefing documents recommend against adding KPV — or any of the seven PCAC peptides — to the 503A Bulks List, citing limited human data and unassessed immunogenicity risk.

What KPV is and where it comes from

KPV is the C-terminal tripeptide sequence of α-MSH, composed of lysine, proline, and valine (H-Lys-Pro-Val-OH), with a molecular weight of 342.43 Da. The full α-MSH molecule is large and has broad receptor effects; researchers identified that the C-terminal tripeptide retains much of α-MSH's anti-inflammatory activity in a more stable, smaller form. Its compact backbone provides partial resistance to digestive enzymes, and its specific amino-acid sequence enables direct interaction with immune cells — a property that has made it attractive across several inflammatory disease contexts.

KPV arises naturally when α-MSH is enzymatically cleaved in tissues under stress, meaning it is, in origin, a physiological fragment rather than a synthetic construct. That origin has informed research hypotheses around tolerability: because it derives from a natural hormone the body produces, KPV has not shown significant adverse effects at physiological doses in available research, though long-term human safety data do not yet exist.

Mechanism of action: NF-κB inhibition via the PepT1 transporter

The research interest in KPV centres on a two-step intracellular mechanism. First, the peptide is actively transported into intestinal epithelial cells and immune cells via the PepT1 di/tripeptide transporter — a route that provides oral bioavailability to gut tissue without reliance on passive membrane diffusion. Oral bioavailability is lower than injectable forms, but direct delivery to gut tissue may be advantageous for gastrointestinal conditions.

Second, once inside the cell, KPV blocks NF-κB's translocation to the nucleus — the master switch the body uses to activate genes encoding pro-inflammatory cytokines including IL-1β, TNF-α, IL-6, and IL-8. KPV also downregulates the MAPK cascade pathway, reducing the downstream synthesis of pro-inflammatory mediators. This dual pathway suppression, operating at the transcription-factor level rather than at a cell-surface receptor, is proposed as the basis for its activity across tissue types.

A further property noted in preclinical studies: many anti-inflammatory drugs decrease immune function, but KPV does not, making its dual anti-inflammatory and antimicrobial action potentially useful in disorders where infection and inflammation coexist — a profile of interest in wound care settings.

State of the preclinical evidence

Inflammatory bowel disease

The landmark reference in KPV research remains the 2008 Gastroenterology study by Dalmasso and colleagues, which demonstrated that KPV is transported into colonic cells via PepT1 and reduces DSS- and TNBS-induced colitis in mice; oral KPV decreased pro-inflammatory cytokine expression and attenuated disease severity across multiple colitis models.

A 2016 study in Cellular and Molecular Gastroenterology and Hepatology extended this work, showing that KPV dramatically reduced colonic tumorigenesis in a mouse model of colitis-associated cancer, with the effect abolished in PepT1-knockout mice, confirming PepT1 dependence.

Despite this preclinical depth, the body of KPV research consists almost entirely of preclinical studies using cell culture and animal models; no large-scale human clinical trials have been completed. The translational gap is the principal weakness the FDA has flagged in its briefing documents.

Dermatology and wound healing

In skin research, KPV suppresses contact hypersensitivity in mouse models and induces hapten-specific tolerance — an immune memory effect that persists without retreatment and depends on IL-10 signalling. This tolerance induction is proposed as a distinguishing feature relative to conventional topical anti-inflammatories.

A 2025 study published in the Journal of Dermatological Science demonstrated that KPV mitigated fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway, with treatment restoring cell viability and reducing IL-1β secretion in keratinocytes exposed to particulate matter. This adds to a body of in vitro skin immunology work, though robust human evidence for wound healing outcomes is not established and online claims in this area have moved faster than the published literature.

Antimicrobial activity

Alpha-MSH peptides, including KPV, have demonstrated antimicrobial effects against Staphylococcus aureus (including methicillin-resistant strains) and Candida albicans at physiological concentrations. This property, combined with the anti-inflammatory action, has motivated interest in wound care applications where polymicrobial infection and inflammatory dysregulation coincide.

Delivery considerations

KPV can be administered orally, topically, or by subcutaneous injection depending on the target tissue. Its high hydrophilicity limits passive skin penetration, and research into transdermal iontophoretic and nanoparticle delivery systems is ongoing. For gastrointestinal applications, the PepT1 transporter provides a natural oral delivery pathway, an advantage not shared by most larger peptide therapeutics.

Regulatory history and current status

2023–2024: Category 2 restriction

In September 2023, the FDA placed a range of peptides, including KPV, into Category 2 of the 503A Bulk Drug Substances list — a designation that effectively limited or halted legal compounding of these substances by licensed pharmacies for human use, pushing much of the market into unregulated "research chemical" channels.

April 2026: Removal from Category 2

On 22 April 2026, the FDA removed KPV from Category 2 because the nomination was withdrawn by its nominators. Crucially, this removal does not constitute approval; it signals the FDA no longer considers the compound to present significant safety risks at the compounding level, but it does not authorise compounding. KPV now sits in a regulatory grey zone: off the prohibited list, but not yet on the approved list.

July 2026: PCAC review

The FDA's Pharmacy Compounding Advisory Committee will evaluate KPV on 23 July 2026, specifically for wound healing and inflammatory conditions, to determine whether it belongs on the affirmative 503A Bulk Drug Substances List. The committee will hear presentations from the nominators, evaluate background materials, and vote on a recommendation.

FDA's preliminary position

Across all seven peptides under review, FDA cited that the substances are not well-characterised, that there is little or no human evidence of effectiveness for the proposed (mostly injectable) routes, and that there is insufficient human safety data — including unassessed immunogenicity risk. The agency's briefing documents propose the same answer for all seven: do not add them to the list.

Crucially, PCAC recommendations are non-binding. The FDA reviews the committee's recommendation and decides whether to initiate formal rulemaking. Even a positive PCAC recommendation does not immediately authorise compounding — the full rulemaking process, including a proposed rule, public comment period, and final rule, typically takes 12 to 24 months after the hearing.

Implications for UK research procurement

KPV holds no approved drug status in the United Kingdom and is not listed in the MHRA's product licence registry. It falls within the "research use only" category under UK law, meaning it may be procured and used legitimately by licensed research institutions for in vitro and preclinical work, but cannot be prescribed or sold for human administration.

The 23 July PCAC vote will not directly alter KPV's legal standing in the UK. However, the FDA process matters to procurement professionals for three reasons.

First, the FDA's characterisation of the evidence base — specifically the observation that KPV lacks well-characterised physicochemical data and human clinical evidence — establishes a publicly available benchmark for assessing purity and specification claims from suppliers. Laboratories procuring KPV for research should ensure certificates of analysis confirm identity by HPLC and mass spectrometry, and that peptide content and acetate or free-base form are clearly stated.

Second, a positive PCAC recommendation, if it comes, would signal a degree of regulatory confidence in KPV's characterisation that could accelerate pharmaceutical interest and, in turn, quality-controlled supply. A negative outcome is likely to maintain the current environment in which KPV circulates largely through unregulated channels.

Third, if PCAC recommends KPV for inclusion and the FDA ultimately adds it, compounding would become lawful under Section 503A, meaning licensed 503A compounding pharmacies could prepare KPV formulations under physician prescription. A negative outcome would likely close that pathway, leaving research-use supply as the dominant channel.

BSR Intelligence will report on the PCAC vote outcome following the 23–24 July hearing.